80 FR 60414 - Clarifying Current Roles and Responsibilities Described in the Coordinated Framework for the Regulation of Biotechnology and Developing a Long-Term Strategy for the Regulation of the Products of Biotechnology
SCIENCE AND TECHNOLOGY POLICY OFFICE Federal Register Volume 80, Issue 193 (October 6, 2015)
Federal Register Volume 80, Issue 193 (October 6, 2015)
| Page Range | 60414-60416 | |
| FR Document | 2015-25325 |
[Federal Register Volume 80, Number 193 (Tuesday, October 6, 2015)] [Notices] [Pages 60414-60416] From the Federal Register Online [www.thefederalregister.org] [FR Doc No: 2015-25325] ======================================================================= ----------------------------------------------------------------------- SCIENCE AND TECHNOLOGY POLICY OFFICE Clarifying Current Roles and Responsibilities Described in the Coordinated Framework for the Regulation of Biotechnology and Developing a Long-Term Strategy for the Regulation of the Products of Biotechnology AGENCY: National Science and Technology Council, Science and Technology Policy Office. ACTION: Notice of request for information. ----------------------------------------------------------------------- SUMMARY: On July 2, 2015, the Executive Office of the President (EOP) issued a memorandum (Ref. 1) directing the primary agencies that regulate the products of biotechnology--the U.S. Environmental Protection Agency (EPA), the Food and Drug Administration (FDA), and the U.S. Department of Agriculture (USDA)--to update the Coordinated Framework for the Regulation of Biotechnology (51 FR 23302; June 26, 1986) (Ref. 2), develop a long-term strategy to ensure that the Federal biotechnology regulatory system is prepared for the future products of biotechnology, and commission an expert analysis of the future landscape of biotechnology products to support this effort. The memorandum's objectives are to ensure public confidence in the regulatory system and to prevent unnecessary barriers to future innovation and competitiveness by improving the transparency, coordination, predictability, and efficiency of the regulation of biotechnology products while continuing to protect health and the environment. The purpose of this Request for Information (RFI) is to solicit relevant data and information, including case studies, that can assist in the development of the proposed update to the Coordinated Framework for the Regulation of Biotechnology (CF) to clarify the current roles and responsibilities of the EPA, FDA, and USDA and the development of a long-term strategy consistent with the objectives described in the July 2, 2015 EOP memorandum. In addition to this RFI, the update to the CF will undergo public comment before it is finalized. DATES: Responses must be received by November 13, 2015 at 5:00 p.m. EST to be considered. ADDRESSES: You may submit information by either of the following methods (electronic is strongly preferred):Federal eRulemaking Portal: http://www.regulations.gov. Docket No. FDA-2015-N-3403. Follow the instructions for submitting information. Information submitted electronically, including attachments, to http://www.regulations.gov will be posted to the docket unchanged. Mail: National Science and Technology Council: Emerging Technologies Interagency Policy Coordination Committee, Office of Science and Technology Policy, 1650 Pennsylvania Avenue NW., Washington, DC 20504. If submitting a response by mail, please allow sufficient time for mail processing. Written/paper information, including attachments, will be posted to the docket unchanged. Instructions: All submissions received must include Docket No. FDA- 2015-N-3403 for Clarifying Current Roles and Responsibilities Described in the Coordinated Framework for the Regulation of Biotechnology and Developing a Long-Term Strategy for the Regulation of the Products of Biotechnology; Request for Information. Disclaimer: All information received will be placed in the docket and will be publicly viewable at http://www.regulations.gov. Responses must be unclassified and should not contain any information that might be considered proprietary, confidential, or personally identifying (such as home address or social security number). Responses to this RFI will not be returned. The National Science and Technology Council is under no obligation to acknowledge receipt of the information received, or provide feedback to respondents with respect to any information submitted under this RFI. No requests for a bid package or solicitation will be accepted; no bid package or solicitation exists. This RFI is issued solely for information and planning purposes and does not constitute a solicitation. FOR FURTHER INFORMATION CONTACT: National Science and Technology Council: Emerging Technologies Interagency Policy Coordination Committee, Office of Science and Technology Policy, Executive Office of the President, Eisenhower Executive Office Building, 1650 Pennsylvania Ave., Washington DC 20504, Phone: [[Page 60415]] 202-456-4444, Online: https://www.whitehouse.gov/webform/contact-emerging-technologies-interagency-policy-coordinating-committee-national-science-and SUPPLEMENTARY INFORMATION: Background Information In 1986, the Office of Science and Technology Policy (OSTP) issued the Coordinated Framework for the Regulation of Biotechnology (CF), which outlined a comprehensive Federal regulatory policy for ensuring the safety of biotechnology products. The CF sought to achieve a balance between regulation adequate to ensure the protection of health and the environment while maintaining sufficient regulatory flexibility to avoid impeding innovation. In 1992, OSTP issued an update to the CF that sets forth a risk- based, scientifically sound basis for the oversight of activities that introduce biotechnology products into the environment (57 FR 6753; February 27, 1992) (Ref. 3). The update affirmed that Federal oversight should focus on the characteristics of the product, the environment into which it is being introduced, and the intended use of the product, rather than the process by which the product is created. On July 2, 2015 the Executive Office of the President (EOP) issued a memorandum directing the primary Federal agencies that have oversight responsibilities for the products of biotechnology--the U.S. Environmental Protection Agency (EPA), the Food and Drug Administration (FDA), and the U.S. Department of Agriculture (USDA)--to update the CF to clarify the current roles and responsibilities of the agencies that regulate the products of biotechnology, develop a long-term strategy to ensure that the Federal biotechnology regulatory system is prepared for the future products of biotechnology, and commission an independent, expert analysis of the future landscape of biotechnology products. These efforts will build on the regulatory principles described in the CF and the 1992 update to the CF. The memorandum's objectives are to ensure public confidence in the regulatory system and to prevent unnecessary barriers to future innovation and competitiveness by improving the transparency, coordination, predictability, and efficiency of the regulation of biotechnology products while continuing to protect health and the environment. The July 2, 2015 EOP memorandum stated that the update to the CF should clarify the current roles and responsibilities of the agencies that regulate the products of biotechnology by accomplishing the following four objectives: (i) Clarifying which biotechnology product areas are within the authority and responsibility of each agency; (ii) clarifying the roles that each agency plays for different product areas, particularly for those product areas that fall within the responsibility of multiple agencies, and how those roles relate to each other in the course of a regulatory assessment; (iii) clarifying a standard mechanism for communication and, as appropriate, coordination among agencies, while they perform their respective regulatory functions, and for identifying agency designees responsible for this coordination function; and (iv) clarifying the mechanism and timeline for regularly reviewing, and updating as appropriate, the CF to minimize delays, support innovation, protect health and the environment and promote the public trust in the regulatory systems for biotechnology products. As noted in the July 2, 2015 EOP memorandum, ``biotechnology products'' refers to products developed through genetic engineering or the targeted or in vitro manipulation of genetic information of organisms, including plants, animals, and microbes. It also covers some of the products produced by such plants, animals, and microbes or their derived products as determined by existing statutes and regulations. Products such as human drugs and medical devices are not the focus of the activities described in the memorandum. The purpose of this RFI is to solicit relevant data and information, including case studies, that can inform the development of the proposed update to the CF and the development of a long-term strategy consistent with the objectives described in the July 2, 2015 EOP memorandum. In addition to this RFI, the update to the CF will undergo public comment before it is finalized. Information Requested The National Science and Technology Council requests relevant data and information, including case studies, that can inform the update to the CF by clarifying the current roles and responsibilities of the EPA, FDA, and USDA and the development of the long-term strategy consistent with the objectives described in the July 2, 2015 EOP memorandum. For details on the current roles and responsibilities of these agencies, refer to their Web sites. Relevant FDA Web sites http://www.fda.gov/Food/FoodScienceResearch/Biotechnology/ http://www.fda.gov/AnimalVeterinary/DevelopmentApprovalProcess/GeneticEngineering/GeneticallyEngineeredAnimals/ucm113605.htm Relevant EPA Web sites http://www.epa.gov/pesticides/biopesticides/regtools/biotech-reg-prod.htm http://www.epa.gov/biotech_rule/ Relevant USDA Web sites https://www.aphis.usda.gov/wps/portal/aphis/ourfocus/biotechnology A brief summary of these agencies' current roles follows. The FDA regulates products of genetically engineered (GE) organisms that fall within FDA's authority under the Federal Food, Drug, and Cosmetic (FD&C) Act and other statutes. The FDA is responsible for ensuring the safety of all plant-derived human and animal foods, including those that are from genetically engineered sources. FDA also regulates GE animals under the new animal drug provisions of the FD&C Act, and FDA's regulations for new animal drugs. (The actual regulated article is the recombinant DNA construct inserted into a specific site in the genome of an animal; as a shorthand, the FDA refers to the regulation of GE animals.) Within USDA, the Animal and Plant Health Inspection Service (APHIS) is responsible for protecting agriculture from pests and diseases. Under the Plant Protection Act (PPA) and the Animal Health Protection Act (AHPA), USDA-APHIS has regulatory oversight over products of modern biotechnology that could pose a risk to plant and animal health. The AHPA provides authority to prohibit or restrict imports or entry into the United States or dissemination of any pest or disease of livestock. GE animals and insects would be subject to import or transport restrictions if there is a risk to animal health. The PPA, as amended, provides authority to regulate the introduction (i.e., importation, interstate movement, or release into the environment) of certain GE organisms and products. A GE organism is considered a regulated article if the donor organism, recipient organism, vector, or vector agent used in engineering the organism belongs to one of the taxa listed in the regulation and is also considered a plant pest. A GE organism is also regulated when APHIS has reason to believe that the GE organism may be a plant pest. A GE organism is no longer subject to the [[Page 60416]] plant pest provisions of the PPA or to regulatory requirements when APHIS determines that it is unlikely to pose a plant pest risk. The EPA under the Federal Insecticide, Fungicide, and Rodenticide Act (FIFRA) and the FD&C Act regulates the sale and distribution of all pesticides, including those produced through genetic engineering. This includes microorganisms, biochemicals isolated from organisms, and plant-incorporated protectants (PIPs), a type of pesticide intended to be produced and used in living plants. Under the Toxic Substances Control Act (TSCA), EPA has oversight responsibilities for a wide range of commercial, industrial, and consumer applications of microbial biotechnology. New chemicals produced through those microbial biotechnology applications are subject to premanufacturing review under TSCA. Questions Keeping in mind the principles of the regulation of the products of biotechnology as articulated in the CF and the 1992 update to the CF, as well as the objectives of the July 2, 2015 EOP memorandum, respondents are welcome to address one or more of the following questions in regards to the proposed update to the CF and the development of the long-term strategy. Respondents are asked to indicate to which question responses are targeted. 1. What additional clarification could be provided regarding which biotechnology product areas are within the statutory authority and responsibility of each agency? 2. What additional clarification could be provided regarding the roles that each agency plays for different biotechnology product areas, particularly for those product areas that fall within the responsibility of multiple agencies, and how those roles relate to each other in the course of a regulatory assessment? 3. How can Federal agencies improve their communication to consumers, industry, and other stakeholders regarding the authorities, practices, and bases for decision-making used to ensure the safety of the products of biotechnology? 4. Are there relevant data and information, including case studies, that can inform the update to the CF or the development of the long- term strategy regarding how to improve the transparency, coordination, predictability, and efficiency of the regulatory system for the products of biotechnology? 5. Are there specific issues that should be addressed in the update of the CF or in the long-term strategy in order to increase the transparency, coordination, predictability, and efficiency of the regulatory system for the products of biotechnology? References These references are available electronically at http://www.regulations.gov. We have verified the Web site addresses, but we are not responsible for any subsequent changes to Web sites after this document publishes in the Federal Register. 1. Executive Office of the President. Office of Science and Technology Policy, Office of Management and Budget, United States Trade Representative, and Council on Environmental Quality. Modernizing the Regulatory System for Biotechnology Products, July 2, 2015. Available online at: https://www.whitehouse.gov/sites/default/files/microsites/ostp/modernizing_the_reg_system_for_biotech_products_memo_final.pdf. 2. Executive Office of the President. Office of Science and Technology Policy. Coordinated Framework for Regulation of Biotechnology. 51 FR 23302, June 26, 1986. Available online at: http://www.aphis.usda.gov/brs/fedregister/coordinated_framework.pdf 3. Executive Office of the President. Office of Science and Technology Policy. Exercise of Federal Oversight Within Scope of Statutory Authority: Planned Introductions of Biotechnology Products Into the Environment. 57 FR 6753, February 27, 1992. Available online at: https://www.whitehouse.gov/sites/default/files/microsites/ostp/57_fed_reg_6753__1992.pdf Ted Wackler, Deputy Chief of Staff and Assistant Director. [FR Doc. 2015-25325 Filed 10-5-15; 8:45 am] BILLING CODE 3270-F5-P
![60414 Federal Register / Vol. 80, No. 193 / Tuesday, October 6, 2015 / Notices
information before making the comment Dated at Rockville, Maryland, this 29th day RFI, the update to the CF will undergo
submissions available to the public or of September 2015. public comment before it is finalized.
entering the comment into ADAMS. For the Nuclear Regulatory Commission. DATES: Responses must be received by
Tremaine Donnell, November 13, 2015 at 5:00 p.m. EST to
II. Background
NRC Clearance Officer, Office of Information be considered.
Under the provisions of the Services. ADDRESSES: You may submit
Paperwork Reduction Act of 1995 (44 [FR Doc. 2015–25340 Filed 10–5–15; 8:45 am] information by either of the following
U.S.C. Chapter 35), the NRC recently BILLING CODE 7590–01–P methods (electronic is strongly
submitted a request for renewal of an
preferred):
existing collection of information to • Federal eRulemaking Portal: http://
OMB for review entitled, 10 CFR part 51 SCIENCE AND TECHNOLOGY POLICY www.regulations.gov. Docket No. FDA–
‘‘Environmental Protection Regulations OFFICE 2015–N–3403. Follow the instructions
for Domestic Licensing and Related for submitting information. Information
Regulatory Functions.’’ The NRC hereby Clarifying Current Roles and submitted electronically, including
informs potential respondents that an Responsibilities Described in the attachments, to http://
agency may not conduct or sponsor, and Coordinated Framework for the www.regulations.gov will be posted to
that a person is not required to respond Regulation of Biotechnology and the docket unchanged.
to, a collection of information unless it Developing a Long-Term Strategy for • Mail: National Science and
displays a currently valid OMB control the Regulation of the Products of Technology Council: Emerging
number. Biotechnology Technologies Interagency Policy
The NRC published a Federal Coordination Committee, Office of
Register notice with a 60-day comment AGENCY: National Science and
Technology Council, Science and Science and Technology Policy, 1650
period on this information collection on Pennsylvania Avenue NW., Washington,
June 23, 2015 (80 FR 35991). Technology Policy Office.
ACTION: Notice of request for
DC 20504. If submitting a response by
1. The title of the information
information. mail, please allow sufficient time for
collection: 10 CFR part 51
mail processing. Written/paper
‘‘Environmental Protection Regulations
SUMMARY: On July 2, 2015, the Executive information, including attachments, will
for Domestic Licensing and Related
Office of the President (EOP) issued a be posted to the docket unchanged.
Regulatory Functions.’’ Instructions: All submissions received
2. OMB approval number: 3150–0021. memorandum (Ref. 1) directing the
3. Type of submission: Extension. primary agencies that regulate the must include Docket No. FDA–2015–N–
4. The form number if applicable: Not products of biotechnology—the U.S. 3403 for Clarifying Current Roles and
applicable. Environmental Protection Agency Responsibilities Described in the
5. How often the collection is required (EPA), the Food and Drug Coordinated Framework for the
or requested: Upon submittal of an Administration (FDA), and the U.S. Regulation of Biotechnology and
application for a combined license, Department of Agriculture (USDA)—to Developing a Long-Term Strategy for the
construction permit, operating license, update the Coordinated Framework for Regulation of the Products of
operating license renewal, early site the Regulation of Biotechnology (51 FR Biotechnology; Request for Information.
permit, design certification, 23302; June 26, 1986) (Ref. 2), develop Disclaimer: All information received
decommissioning or license termination a long-term strategy to ensure that the will be placed in the docket and will be
review, or manufacturing license, or Federal biotechnology regulatory system publicly viewable at http://
upon submittal of a petition for is prepared for the future products of www.regulations.gov. Responses must
rulemaking. biotechnology, and commission an be unclassified and should not contain
6. Who will be required or asked to expert analysis of the future landscape any information that might be
respond: Licensees and applicants of biotechnology products to support considered proprietary, confidential, or
requesting approvals for actions this effort. The memorandum’s personally identifying (such as home
proposed in accordance with the objectives are to ensure public address or social security number).
provisions of 10 CFR parts 30, 32, 33, confidence in the regulatory system and Responses to this RFI will not be
34, 35, 36, 39, 40, 50, 52, 54, 60, 61, 70, to prevent unnecessary barriers to future returned. The National Science and
and 72. innovation and competitiveness by Technology Council is under no
7. The estimated number of annual improving the transparency, obligation to acknowledge receipt of the
responses: 48.7. coordination, predictability, and information received, or provide
8. The estimated number of annual efficiency of the regulation of feedback to respondents with respect to
respondents: 48.7. biotechnology products while any information submitted under this
9. An estimate of the total number of continuing to protect health and the RFI. No requests for a bid package or
hours needed annually to comply with environment. solicitation will be accepted; no bid
the information collection requirement The purpose of this Request for package or solicitation exists. This RFI
or request: 48,104. Information (RFI) is to solicit relevant is issued solely for information and
10. Abstract: The NRC’s regulations at data and information, including case planning purposes and does not
10 CFR part 51 specifies information to studies, that can assist in the constitute a solicitation.
be provided by applicants and licensees development of the proposed update to FOR FURTHER INFORMATION CONTACT:
so that the NRC can make the Coordinated Framework for the National Science and Technology
tkelley on DSK3SPTVN1PROD with NOTICES
determinations necessary to adhere to Regulation of Biotechnology (CF) to Council: Emerging Technologies
the policies, regulations, and public clarify the current roles and Interagency Policy Coordination
laws of the United States, which are responsibilities of the EPA, FDA, and Committee, Office of Science and
interpreted and administered in USDA and the development of a long- Technology Policy, Executive Office of
accordance with the provisions set forth term strategy consistent with the the President, Eisenhower Executive
in the National Environmental Policy objectives described in the July 2, 2015 Office Building, 1650 Pennsylvania
Act of 1969, as amended. EOP memorandum. In addition to this Ave., Washington DC 20504, Phone:
VerDate Sep<11>2014 18:31 Oct 05, 2015 Jkt 238001 PO 00000 Frm 00066 Fmt 4703 Sfmt 4703 E:\FR\FM\06OCN1.SGM 06OCN1](https://thefederalregister.org/doc/80_FR_60607/page/1.svg)
![60416 Federal Register / Vol. 80, No. 193 / Tuesday, October 6, 2015 / Notices
plant pest provisions of the PPA or to 5. Are there specific issues that more of the exemptions set forth in 5
regulatory requirements when APHIS should be addressed in the update of the U.S.C. 552b(c)(3), (5), (7), 9(B) and (10)
determines that it is unlikely to pose a CF or in the long-term strategy in order and 17 CFR 200.402(a)(3), (5), (7), 9(ii)
plant pest risk. to increase the transparency, and (10), permit consideration of the
The EPA under the Federal coordination, predictability, and scheduled matter at the Closed Meeting.
Insecticide, Fungicide, and Rodenticide efficiency of the regulatory system for Commissioner Stein, as duty officer,
Act (FIFRA) and the FD&C Act regulates the products of biotechnology? voted to consider the items listed for the
the sale and distribution of all References Closed Meeting in closed session.
pesticides, including those produced The subject matter of the Closed
through genetic engineering. This These references are available Meeting will be:
includes microorganisms, biochemicals electronically at http://
www.regulations.gov. We have verified Institution and settlement of
isolated from organisms, and plant- injunctive actions;
incorporated protectants (PIPs), a type the Web site addresses, but we are not
responsible for any subsequent changes Institution and settlement of
of pesticide intended to be produced administrative proceedings;
and used in living plants. Under the to Web sites after this document
publishes in the Federal Register. Adjudicatory matters; and
Toxic Substances Control Act (TSCA),
EPA has oversight responsibilities for a 1. Executive Office of the President. Office of
Other matters relating to enforcement
wide range of commercial, industrial, Science and Technology Policy, Office of proceedings.
and consumer applications of microbial Management and Budget, United States At times, changes in Commission
biotechnology. New chemicals Trade Representative, and Council on priorities require alterations in the
produced through those microbial Environmental Quality. Modernizing the scheduling of meeting items.
Regulatory System for Biotechnology For further information and to
biotechnology applications are subject Products, July 2, 2015. Available online
to premanufacturing review under at: https://www.whitehouse.gov/sites/
ascertain what, if any, matters have been
TSCA. default/files/microsites/ostp/ added, deleted or postponed, please
modernizing_the_reg_system_for_ contact the Office of the Secretary at
Questions biotech_products_memo_final.pdf. (202) 551–5400.
Keeping in mind the principles of the 2. Executive Office of the President. Office of Dated: October 1, 2015.
regulation of the products of Science and Technology Policy.
Coordinated Framework for Regulation Brent J. Fields,
biotechnology as articulated in the CF Secretary.
of Biotechnology. 51 FR 23302, June 26,
and the 1992 update to the CF, as well 1986. Available online at: http:// [FR Doc. 2015–25451 Filed 10–2–15; 11:15 am]
as the objectives of the July 2, 2015 EOP www.aphis.usda.gov/brs/fedregister/ BILLING CODE 8011–01–P
memorandum, respondents are welcome coordinated_framework.pdf
to address one or more of the following 3. Executive Office of the President. Office of
questions in regards to the proposed Science and Technology Policy. Exercise
of Federal Oversight Within Scope of
SECURITIES AND EXCHANGE
update to the CF and the development
Statutory Authority: Planned COMMISSION
of the long-term strategy. Respondents
are asked to indicate to which question Introductions of Biotechnology Products
Into the Environment. 57 FR 6753, [Release No. 34–76059; File No. SR–FINRA–
responses are targeted.
February 27, 1992. Available online at: 2015–033]
1. What additional clarification could https://www.whitehouse.gov/sites/
be provided regarding which default/files/microsites/ostp/57_fed_reg_ Self-Regulatory Organizations;
biotechnology product areas are within 6753__1992.pdf Financial Industry Regulatory
the statutory authority and Authority, Inc.; Notice of Filing of a
Ted Wackler,
responsibility of each agency? Proposed Rule Change To Amend
2. What additional clarification could Deputy Chief of Staff and Assistant Director.
FINRA Rule 0150 to Apply FINRA Rule
be provided regarding the roles that [FR Doc. 2015–25325 Filed 10–5–15; 8:45 am]
2121 and its Supplementary Material
each agency plays for different BILLING CODE 3270–F5–P
.01 and .02 to Transactions in
biotechnology product areas, Exempted Securities That Are
particularly for those product areas that Government Securities
fall within the responsibility of multiple SECURITIES AND EXCHANGE
agencies, and how those roles relate to COMMISSION September 30, 2015.
each other in the course of a regulatory Pursuant to Section 19(b)(1) of the
assessment? Sunshine Act Meeting Securities Exchange Act of 1934
3. How can Federal agencies improve Notice is hereby given, pursuant to (‘‘Act’’) 1 and Rule 19b–4 thereunder,2
their communication to consumers, the provisions of the Government in the notice is hereby given that on
industry, and other stakeholders Sunshine Act, Public Law 94–409, that September 17, 2015, Financial Industry
regarding the authorities, practices, and the Securities and Exchange Regulatory Authority, Inc. (‘‘FINRA’’)
bases for decision-making used to Commission will hold a Closed Meeting filed with the Securities and Exchange
ensure the safety of the products of on Thursday, October 8, 2015 at 2:00 Commission (‘‘SEC’’ or ‘‘Commission’’)
biotechnology? p.m. the proposed rule change as described
4. Are there relevant data and Commissioners, Counsel to the in Items I, II, and III below, which Items
information, including case studies, that Commissioners, the Secretary to the have been substantially prepared by
tkelley on DSK3SPTVN1PROD with NOTICES
can inform the update to the CF or the Commission, and recording secretaries FINRA. The Commission is publishing
development of the long-term strategy will attend the Closed Meeting. Certain this notice to solicit comments on the
regarding how to improve the staff members who have an interest in proposed rule change from interested
transparency, coordination, the matters also may be present. persons.
predictability, and efficiency of the The General Counsel of the
regulatory system for the products of Commission, or her designee, has 1 15 U.S.C. 78s(b)(1).
biotechnology? certified that, in her opinion, one or 2 17 CFR 240.19b–4.
VerDate Sep<11>2014 18:31 Oct 05, 2015 Jkt 238001 PO 00000 Frm 00068 Fmt 4703 Sfmt 4703 E:\FR\FM\06OCN1.SGM 06OCN1](https://thefederalregister.org/doc/80_FR_60607/page/3.svg)
Document Created: 2015-12-15 08:50:52
Document Modified: 2015-12-15 08:50:52
| Category | Regulatory Information | |
| Collection | Federal Register | |
| sudoc Class | AE 2.7: GS 4.107: AE 2.106: | |
| Publisher | Office of the Federal Register, National Archives and Records Administration | |
| Section | Notices | |
| Action | Notice of request for information. | |
| Dates | Responses must be received by November 13, 2015 at 5:00 p.m. EST to be considered. | |
| Contact | National Science and Technology Council: Emerging Technologies Interagency Policy Coordination Committee, Office of Science and Technology Policy, Executive Office of the President, Eisenhower Executive Office Building, 1650 Pennsylvania Ave., Washington DC 20504, Phone: 202-456-4444, Online: https://www.whitehouse.gov/webform/contact- emerging-technologies-interagency-policy-coordinating-committee- national-science-and | |
| FR Citation | 80 FR 60414 |
2025 Federal Register | Disclaimer | Privacy Policy
USC | CFR | eCFR